Panthera Biopartners (Panthera) is the UK’s largest Site Management Organisation (SMO) for commercial clinical trials.
Based in Preston, Lancashire, Panthera specialises in the recruitment of patients and running of Phase II and Phase III clinical trials across a broad spectrum of therapeutic areas including vaccines, cardiovascular medicine, diabetes, neurology, respiratory medicine, dermatology, rheumatology and early dementia trials. Its service offering spans trial planning, data collection and patient retention. It operates six UK sites and provides clinical trials for many of the largest pharmaceutical companies and clinical research organisations (CROs) globally.
Scaling and expanding
In August 2025, LDC backed Panthera’s existing management team, led by CEO Stuart Young, CCO Chris Dodd, CFO Rory Lloyd, CMO Dr. Mahadev Ramjee and CIO Andy Broomhead, to support an ambitious growth strategy underpinned by further expanding its operations in the UK and Europe, increasing its number of clinical sites, investing in technology, and scaling its trial delivery capabilities.
We’re excited to partner with LDC for this next phase of growth. Their investment will help us accelerate expansion, enhance our capabilities, and continue delivering for our clients and patients. We look forward to broadening our reach into Europe and expanding access to clinical trials across new regions.”
How Panthera is fuelling the UK’s life sciences strategy
LDC’s partnership with Panthera was featured in The Times, highlighting the UK’s ambition to become Europe’s leading life sciences economy and the crucial role businesses like Panthera are playing.
Download the article